Efficacy of Kangliuwan for Recurrent Grade IV Glioma

NCT03949192 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2020-05-05

No results posted yet for this study

Summary

A Prospective Exploratory Clinical Study to explore the efficacy of Hospital Traditional Chinese Medicine Preparation Kangliuwan for Recurrent Grade IV Glioma.

Conditions

  • Glioma of Brain
  • Recurrence

Sponsors & Collaborators

  • Xuanwu Hospital, Beijing

    lead OTHER

Principal Investigators

  • Qingtang Lin, M.D., Ph.D. · Xuanwu Hospital, Beijing

  • Xiaolan Lin, M.D. · Xuanwu Hospital, Beijing

  • Ling Chen, M.D. · The General Hospital of People's Liberation Army (301 hospital)

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-28
Primary Completion
2021-06-30
Completion
2021-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03949192 on ClinicalTrials.gov